Literature DB >> 11157644

New anticoagulant drugs.

J I Weitz1, J Hirsh.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11157644     DOI： 10.1378/chest.119.1_suppl.95s

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  14 in total

1.  Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids.

Authors:  Brian L Henry; Jay N Thakkar; Erika J Martin; Donald F Brophy; Umesh R Desai
Journal:  Blood Coagul Fibrinolysis       Date:  2009-01       Impact factor: 1.276

2.  Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.

Authors:  R De Cristofaro; V De Filippis
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

Review 3.  Bivalirudin: a review of its potential place in the management of acute coronary syndromes.

Authors:  Christopher I Carswell; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Authors:  Linda C Johansson; Lars Frison; Ulrika Logren; Gunnar Fager; David Gustafsson; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.

Authors:  Ulf G Eriksson; Jaap W Mandema; Mats O Karlsson; Lars Frison; Per Olsson Gisleskog; Ulrika Wählby; Bengt Hamrén; David Gustafsson; Bengt I Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.

Authors:  Ulf G Eriksson; Susanne Johansson; Per-Ola Attman; Henrik Mulec; Lars Frison; Gunnar Fager; Ola Samuelsson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  On the modeling of snake venom serine proteinase interactions with benzamidine-based thrombin inhibitors.

Authors:  Elsa S Henriques; Nelson Fonseca; Maria João Ramos
Journal:  Protein Sci       Date:  2004-09       Impact factor: 6.725

8.  Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.

Authors:  Ulf G Eriksson; Ulf Bredberg; Kristina Gislén; Linda C Johansson; Lars Frison; Martin Ahnoff; David Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2003-03-27       Impact factor: 2.953

Review 9.  Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?

Authors:  John W Eikelboom; John French
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Patients with chronic kidney disease/diabetes mellitus: the high-risk profile in acute coronary syndrome.

Authors:  Usman Baber; Uschi Auguste
Journal:  Curr Cardiol Rep       Date:  2013-08       Impact factor: 2.931
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.